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SpainWith a highly immunized population, rubella infection in Spain is so low that the WHO has declared the
elimination of rubella. Rubella in pregnant women is also very rare. The objective of this study is to
describe the last cases of congenital rubella syndrome reported and recommend actions to maintain
the status of the disease as eliminated.
The CRS cases reported to the Spanish National Epidemiological Surveillance Network between 1997
and 2016 were studied, and the epidemiological, clinical, diagnostic and maternal characteristics of new-
borns with CRS described. The incidence of CRS was calculated using Birth Statistics from the Spanish
National Statistics Agency (INE).
Twenty-three cases of CRS were reported, 70% of which were associated with rubella outbreaks. The
most common clinical conditions were heart disease (52.2%), deafness (39.1%) and cataracts (30.4%);
91.3% of cases were confirmed by laboratory testing. 70.0% were born from a non-vaccinated foreign
mother, resident in Spain (cumulative rate incidence (CR): 1.1/100,000 births), with mothers coming
from Africa (36.0%), Latin America (29.0%), Eastern Europe (21.0%) and Asia (14.0%). Six were born to
Spanish mothers (CR: 0.08/ 100,000 births), the last of which were in 2005.
The majority of CRS cases were born to unvaccinated immigrant women infected in Spain during
rubella outbreaks. Universal vaccination in childhood is the most efficient strategy to prevent rubella.
The limited circulation of the virus will, however, quickly lead to a loss of awareness about rubella among
clinicians and epidemiologists. It is necessary to maintain protocols capable of identifying signs consis-
tent with rubella in pregnant women and signs suggestive of congenital rubella in newborns.
 2018 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Rubella infection during pregnancy can produce spontaneous
miscarriage, death of the foetus or the group of symptoms known
as Congenital Rubella Syndrome (CRS), hence the importance of
rubella prevention for public health.
Both the level of risk and the kind of defect depend on the ges-
tational age at the moment of infection. If during the first
12 weeks, up to 85% of foetuses will present congenital abnormal-ities; between the 13th and 16th weeks the risk drops to 10–20%,
with malformations becoming rare after the 20th week [1].
Hearing impairment is the most common, and frequently only,
symptom of CRS. It can also present itself as eye problems, heart or
craniofacial defects, or temporary issues such as purpura, menin-
goencephalitis, an enlarged liver or spleen, and radiolucent bone
diseases in longer bones. Those children who survive infancy
may suffer from developmental delays, type 1 diabetes mellitus,
or thyroiditis [1,2].
The elimination of a disease is the reduction to zero of the inci-
dence of endemic disease caused by a specific agent in a defined
geographical area as a result of deliberate efforts. In 1998 the
WHO launched an initiative to eliminate measles in Europe. In
2005 they added the ambition to eliminate rubella and prevent
CRS (<1 case per 100,000 living newborns each year) by 2010 [3].
170 E.M. Seppälä et al. / Vaccine 37 (2019) 169–175The region has not succeeded in this objective, and the WHO is
evaluating each country on an individual basis, and declaring elim-
ination as appropriate. It is necessary to maintain surveillance and
immunization strategies, with necessary immunization rates
above 95% using the MMR (Measles, Mumps and Rubella) vaccine
in childhood and vaccinating any person susceptible to measles
or rubella, irrespective of age [4].
The primary objective of rubella vaccination is to prevent the
effects of infection on the foetus. Although 78% of countries vacci-
nate against rubella, in many places it is still endemic. On a world
level, rubella is one of the main infection-related causes of birth
defects. The highest risk of CRS is found in countries without
rubella vaccination programmes, or with programmes which have
only been introduced recently with as yet high levels of suscepti-
bility among women of a fertile age [5,6].
In Spain, the first attempts to prevent the congenital effects of
rubella began in 1978, with a programme to immunize girls in
schools at 11 years old. Just after, in 1981, the MMR jab was intro-
duced to the infant vaccination schedule; a second dose was added
in 1996 [7]. In 2012 the age of first MMR dose administration was
brought forward to 12 months (first dose) and 3–4 years old (sec-
ond dose) [8,9].
In order to monitor the impact of the vaccination programme,
rubella was included in the list of diseases that must be officially
reported to the Spanish National Epidemiological Surveillance Net-
work (RENAVE) in 1981, and CRS was subsequently added in 1995.
It is assumed that there is a CRS underreporting between 1995 and
1999. Achieving high levels of immunization in the general popu-
lation led to cases of rubella practically disappearing. In 2008, to
adapt to epidemiological realities, protocols were updated to
improve the sensitivity and the specificity of the surveillance.
Some key points for improving surveillance were introduced: the
confirmation by laboratory testing of all suspected cases of rubella
or CRS, the follow-up of rubella in any pregnant women through to
the end of the pregnancy and the active searching for CRS cases in
the National Hospitalization Discharge Registry [10,11].
A case which is consistent with CRS presents at least two symp-
toms from Group A (hearing impairment, congenital heart condi-
tion, cataracts, congenital glaucoma or pigmentary retinopathy),
or at least one symptom from Group A and one more from Group
B (purpura, splenomegaly, microcephaly, delayed development,
meningoencephalitis, radiolucent bone disease, or neonatal jaun-
dice which appears within 24 h of birth). A positive laboratory
result confirms the case, even if it does not fit the clinical criteria
[12,13].Table 1
Cases of Congenital Rubella Syndrome by Autonomous Community and reporting year. Sp
Year
Autonomous Community 1997 1998 1999 2002 2004
Andalusia 1**
Asturias
Canary Islands 1** 1**
Catalonia 1 1
Castilla-La Mancha
Galicia
Madrid 1 1**,^
Murcia 1**
The Basque Country
C. Valenciana 1**
Total 3 2 1 1 2
Source: National Epidemiology Centre, ISCIII. National Hospitalization Discharge Registr
* Only those years when cases were reported.
** Case recovered from the National Hospitalization Discharge Registry.
^ Case born in Castilla y León but reported in the Autonomous Community of MadridIn Spain, vaccinating infants with the MMR jab drastically
reduced the incidence of rubella, going from 424 cases per
100,000 in 1983 to 1.32 cases per 100,000 in 1999. The last out-
breaks were reported in 2012. Since 2013 endemic transmission
has been prevented and only imported cases have been reported.
An imported case is when the newborn’s mother was in a country
in which rubella remains endemic anytime during gestation, and
which lacks a link with a rubella case in the home country [12].
The aim of our study is to update CRS epidemiology in Spain by
describing the characteristics of the CRS cases, both mothers and
children, reported to the RENAVE between 1997 and 2016. Further
actions that need to be taken to prevent congenital rubella are
discussed.2. Material and methods
We analysed CRS cases reported to the RENAVE between 1997
and 2016. Additionally, we reviewed the annual reports from the
National Measles and Rubella Elimination Programme as well as
other relevant national and international publications [14–19].
We also analysed the clinical characteristics of the cases, the
moment and place of infection and the laboratory diagnosis.
Mothers’ origins, vaccination status, their clinical histories of
rubella during pregnancy and the results of laboratory tests were
studied. The incidence of CRS was calculated using Birth Statistics
from the Spanish National Statistics Agency (INE) [20].3. Results
Between 1997 and 2016, 23 cases of CRS across 10 autonomous
communities were reported. In 2000, 2001, 2003, 2006, 2007,
2010, 2015 and 2016 no cases were reported. 13 cases were
reported and investigated through the CRS surveillance system
and the others were identified retrospectively in the national data-
base of hospital discharges (Table 1). Of the 22 cases of which the
sex is known, 14 were male (63.6%). The incidence rate of CRS for
1997–2016 was 0.26 cases per 100,000 births (annual range 0.00–
1.29). The majority of the children with CRS were born between
September and February.
In 21 cases (91.3%) the clinical presentation is known. Of these,
16 (76.2%) presented at least one symptom from Group A, addi-
tionally 16 cases (76.2%) presented at least one from Group B. 14
cases (66.6%) fulfilled the clinical criteria for a CRS case. The most
common symptoms were from Group A: congenital heart diseaseain, 1997–2016.*
2005 2008 2009 2012 2013 2014 Total
1** 1 3
2** 2
2
1 1 1 5
1** 1 2
1 1
2 4
1
1 1
1 2
6 2 1 3 1 1 23
y, Ministry of Health.
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E.M. Seppälä et al. / Vaccine 37 (2019) 169–175 171(12, 57.1%), impaired hearing (9, 42.8%) and cataracts (7, 33.3%)
(Table 2).
Seven cases were considered imported (30.4%) and 16 endemic
(69.6%) (Table 3). The endemic CRS cases were associated with epi-
demics or outbreaks of rubella (Fig. 1).
In 20 cases (86.9%) the age of baby when the diagnosis was
established is known. In 15 the diagnosis was made in the first
month after birth; three (15.0%) were diagnosed at a month, and
two (10%) at two or more months.
21 CRS cases (91.3%) were confirmed by laboratory testing,
mostly by IgM serology. For the virological study, in 10 cases sam-
ples of urine or nasopharyngeal exudate were collected. Between
1997 and 2007 the viral genotype was characterized in three cases:
a 1E genotype in 1998 and two 1J in 2005. Since 2008 in only two
cases has the genotype been identified (2B) (Table 4).3.1. Maternal characteristics
The mean age at the time of giving birth was 26.5 (range 14–
40). The vaccination status of 12 mothers is unknown (51.2%); of
those that remain (47.8%) only one believed herself to have been
vaccinated, although this was without confirming documentation.
14 cases (70.0%) were born to foreign mothers: Morocco and Sub-
Saharan Africa (35.7%), Latin America (28.6%), Eastern Europe
(21.4%) and Southwest Asia (14.3%) (Table 3). The incidence rate
of CRS from 1997 to 2016 was 1.10 per 100,000 births to foreign
mothers (range 0.00 to 7.14) and 0.08 per 100,000 Spanish-born
mothers (range 0.00–0.51) [Incidence rate ratio = 12.9; CI(95%)
= 4.9–33.5; p < 0.0001].
A total of 17 mothers (73.9%) suffered a rubella-like disease dur-
ing pregnancy: 14 (82.3%) during the first trimester, two (11.8%)
during the second and one (5.9%) during the third.
Serology was carried out for 10 mothers during their pregnan-
cies. Three had positive IgM results and in another three, serocon-
version was identified during pregnancy (Fig. 2).4. Discussion
The WHO declared Spain free of rubella and congenital rubella
in 2015, while in other countries across Europe and the world
rubella continues to be endemic. We have presented the cases of
congenital rubella from the last 20 years. The results show the
impact of the vaccination strategies that have been introduced
and the effect of immigration on CRS epidemiology.
Between 1997 and 2016, the objective of elimination was
achieved, with < 1 case of CRS per 100,000 live births [3]. The
exception was in 2006 when six cases were reported
(1.29/100,000 live births), which coincided with a period of high
circulation of rubella virus in a number of autonomous communi-
ties [15,16,18].
In Spain the combined strategy of selective vaccination of fertile
age women and universal vaccination of infants has achieved the
elimination of rubella and congenital rubella within 30 years. The
vaccination campaigns aimed at adolescents in school contributed
substantially to the control of CRS in the birth cohorts that has not
as yet benefited from vaccination as infants [7]. The programme
was instituted in 1978, and complemented by catch-up campaigns
offering the vaccination to all adolescents born from 1964 onwards
[21]. Therefore Spain-native women born since 1964 received at
least one dose of rubella vaccine while those born since 1986 have
received two doses.
As a result of improving coverage with the MMR vaccine -since
1999 national coverage has exceeded 95% for the first dose and 90%
for the second dose- immunity against rubella was strengthened.
By 1996, 94% of the general population and 96% of women had
Table 3
Congenital Rubella Syndrome. Cases according to mother’s birth country. Spain, 1997–2016.*
Year
Country 1997 1998 1999 2002 2004 2005 2008 2009 2012 2013 2014 Total
Europe Spain 1 1 1 + 1** 2 6
Poland 1 1
Romania 1** 1 2
Africa Ecuatorial Guinea 1** 1 2
Malawi 1** 1
Morocco 1 1** 2
America Colombia 3 3
Dominican Republic 1 1
Asia Philippines 1** 1
Pakistan 1** 1
Unknown 2 1 3
Total 3 2 1 1 2 6 2 1 3 1 1 23
Source: National Epidemiology Centre, ISCIII.
* Only those years when cases were reported.
** Imported case.
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Fig. 1. Incidence of rubella and endemic cases of Congenital Rubella Syndrome by year. Spain, 1982–2016.
172 E.M. Seppälä et al. / Vaccine 37 (2019) 169–175antibodies against rubella [18]. Consequently, the epidemiology of
rubella moved to an elimination profile, presenting since 1999 a
very low incidence and a displacement of the disease towards
adults, including women of fertile age [18]. Between 2008 and
2016, 54.4% (99/182) of confirmed cases were found in unvacci-
nated adults; 28.6% (52/182) had been born outside of Spain, for
the most part in Romania [9].
Congenital rubella arises in association, both temporally and
geographically, with epidemics and outbreaks of rubella [22].
In our study, the majority of children with CRS were born
between September and February, a consequence of the seasonal
distribution of rubella cases, which occur during late winter and
spring.The greater part of our cases were classified as endemic as the
mothers, both Spanish and foreign, were infected during the course
of a rubella outbreak in Spain. Those CRS cases born in 1997–1998
are associated with the epidemic peak that occurred in 1995–1997
[18]; those born in 2004–2005 were a consequence of the out-
breaks reported in the Latin-American population of Madrid
[14,15], and Barcelona [16]; the CRS cases in 2008 coincided with
an outbreak in Algeciras (Andalusia) [17] and other clusters
reported in Catalonia, Madrid and the autonomous community of
Valencia [9]; those born in 2012–2013 were related to outbreaks
which occurred among Romania-origin population residing in
Spain, coinciding with a rubella epidemic in Romania between
2011 and 2012 [9,23].
Undertaken
10 mothers 
(43.5%)
Not undertaken or 
no information
13 mothers
(56.5%) 
Rubella study
during pregnancy 
1st trimester  
8 mothers
2nd trimester  
2 mothers 
IgM (+) 
2 mothers 
IgG (+) 
3 mothers 
IgM (–)
seroconversion
during pregnancy
3 mothers 
2nd trimester
1 mother
3rd trimester 
2 mothers 
IgM (+)  
1 mother 
IgG (+) 
1 mother 
Fig. 2. Congenital Rubella Syndrome. Results of rubella serology carried out on mothers during pregnancy, Spain 1997–2016.
Table 4
Congenital Rubella Syndrome. Clinical samples and results of laboratory tests. Spain, 1997–2016.
CRS identifier Year of case Autonomous community Serum 1 Serum 2 PharyngealExudate Urine Genotype
IgM IgG IgGavidity IgM IgG IgGavidity PCR PCR
SRC1997/1 1997 Valencia
SRC1997/2 1997 Catalonia Pos Pos
SRC1997/3 1997 Canaries Pos
SRC1998/1 1998 Murcia Pos
SRC1998/2 1998 Canaries Pos Pos 1E
SRC1999/1 1999 Madrid Pos
SRC2002/1 2002 Madrid Pos
SRC2004/1 2004 Catalonia Pos Pos Low Neg Neg
SRC2004/2 2004 Andalusia Pos
SRC2005/1 2005 Catalonia Pos
SRC2005/2 2005 Madrid Pos Pos 1J
SRC2005/3 2005 Madrid Pos Pos
SRC2005/4 2005 Galicia Pos Pos 1J
SRC2005/5 2005
SRC2005/6 2005 Valencia Pos
SRC2008/1 2008 Andalusia Neg Pos Low
SRC2008/2 2008 Catalonia Pos Pos Pos
SRC2009/1 2009 The Basque Country Pos
SRC2012/1 2012 Catalonia Pos Pos Pos
SRC2012/2 2012 Asturias Pos Pos
SRC2012/3 2012 Asturias Pos
SRC2013/1 2013 Castilla-La Mancha Pos Pos Pos Pos 2B
SRC2014/1 2014 Andalusia Pos Pos Pos Pos 2B
Source: National Epidemiology Centre, ISCIII.
E.M. Seppälä et al. / Vaccine 37 (2019) 169–175 173It’s worth noting that we cannot discount underreporting of CRS
associated to the rubella epidemic occurring in 1995–1997.
Although CRS was added to the list of mandatory reporting dis-
eases in 1995, it is well known the lack of awareness about the
notification and investigation of suspected disease cases just after
launching a surveillance system.The epidemiology of rubella in Spain correlates with the
evolution of immigration into the country. The number of
immigrants increased by a factor of 10 between 1997 and
2011 (from 609,813 to 5,751,487). Between 2001 and 2005 the
largest influx came from Latin America and afterwards, between
2005 and 2011, immigrants mostly came from Romania.
174 E.M. Seppälä et al. / Vaccine 37 (2019) 169–175Immigration from Morocco was constant from 2002 to 2012 but
less significant [24].
The geographical concentration of recent arrivals with high sus-
ceptibility levels passes above the epidemic threshold and allows
outbreaks to develop in the case of an importation. Depending on
the degree of grouping of susceptible individuals, an explosive out-
break may result, like that generated in Madrid [15], or smaller
outbreaks may be produced, as those which occurred in Aragon
in a more dispersed population [9]. This shows the importance of
identifying and vaccinating susceptible individuals, above all those
who have recently arrived from other countries, international pas-
sengers and health-care workers who can produce and spread out-
breaks of rubella and other epidemic diseases [25].
The identification of the genotype can help to know the circula-
tion of rubella virus along the time. Genotype 1E was predominant
between 1998 and 2003 and was subsequently replaced world-
wide by Genotype 2B. The 1J genotype, identified in 2005, is similar
to others identified at that time in Brazil [19].
Only six cases from our data set were born to Spanish mothers,
the last in 2005. These mothers were more likely to be unprotected
because either they had been born before 1986 or they belonged to
disadvantaged groups (at least two of the studiedmothers belonged
to a Roma community). Since 2008 all of the childrenwith CRSwere
born to unvaccinated non-native mothers, who were infected in
pregnancy during a visit to their country of origin or who con-
tracted the disease during an outbreak of rubella in Spain.
Between 2003 and 2008 [23–28] Spanish expectant mothers
showed lower levels of susceptibility (2.8–4.6%) than non-natives
(7.6–7.7%). These mothers born outside of Spain exceeded the limit
of susceptibility to rubella set by theWHO (<5% of fertile age moth-
ers) [3,10] affecting the control of CRS in Spain [11]. Immigration to
Spain and its demographic profile have both changed over the last
ten years. As a consequence, we need to update the levels of sus-
ceptibility to rubella of women in Spain. It is hoped that the second
national seroepidemiologic study, conducted in 2017, will provide
information relevant for the identification of at risk populations
and help orient future actions for the prevention of congenital
rubella.
The countries of Africa, the Eastern Mediterranean and South-
east Asia record the highest risk of rubella and congenital rubella.
Only the Region of the Americas has been declared rubella-free,
confirming at the same time the elimination of CRS [5,6]. In 2016
the Region of Europe shows a heterogeneous situation: 24 coun-
tries have already reached the rubella elimination, but despite
the introduction of the rubella vaccine across the Region in 2005,
endemic transmission was still occurring in 16 countries. Within
the EU, Poland (533 cases in 2017), Italy, Germany and Romania
continue to report rubella outbreaks and CRS cases [4,6,29].
Continued measures to prevent re-establishment of rubella
transmission are required. The most efficient way to preserve
rubella and CRS elimination is to maintain high levels of infant vac-
cination coverage with two MMR doses. Screening for rubella in
pregnancy and the post-partum vaccination of susceptible women
works as an additional tool to reinforce the immunity of future
mothers and prevent congenital rubella [28]. Nonetheless there is
controversy regarding the utility of screening in populations where
rubella and congenital rubella are rare [30].
In order to document elimination it is necessary to maintain
surveillance protocols which permit the identification and confir-
mation of rubella in pregnant mothers and symptoms suggestive
of congenital rubella in newborns [29]. When the circulation of
the virus is extremely low, the criteria for clinical suspicion must
be very sensitive, in order to facilitate epidemiological and labora-
tory investigation [10,13]. In our data set a third of the cases
showed only one clinical sign; however, they were still reported
and laboratory studies were carried out. The effective surveillanceof congenital rubella requires the contribution of specialist
in epidemiology, paediatrics, gynaecology, cardiology and
ophthalmology.
CRS is not a synonym for congenital rubella infection, which
also produces miscarriages and late stillbirths. The surveillance of
congenital rubella infection is difficult to implement, and it ends
up being more useful to monitor CRS by identifying those cases
with clinical signs [13].
Since 2003 the RENAVE has been notified of eight cases of
rubella during pregnancy, six associated with national outbreaks
and two imported infections. In seven cases the pregnancy was
ended by abortion and in one case of rubella infection in the third
trimester, the pregnancy progressed favourably for both mother
and foetus [9].
Most of CRS reported cases were laboratory confirmed, suggest-
ing those CRS that did not investigated in the laboratory could have
not been reported and consequently they have been lost. Later
identification in national database of hospital discharges improves
knowledge of CRS, and at the same time helps identify weaknesses
in control and surveillance in hospitals [10,12].
5. Conclusions
During the last 20 years, CRS has been rare in Spain. The major-
ity of cases have been born to unvaccinated non-native mothers.
With an extremely low circulation of the virus, we need to know
the susceptibility profile of the population in order to identify sub-
populations at risk of rubella and congenital rubella.
It is necessary to maintain awareness amongst clinicians and
epidemiologists so that signs compatible with rubella can be iden-
tified in pregnancy, and signs suggestive of congenital rubella in
newborns.
The most efficient measure to prevent rubella is to maintain
high vaccination levels with universal vaccination in infancy. Iden-
tifying and vaccinating all susceptible individuals, either through
specific programmes or by taking advantage of any contact with
health services, contributes to the prevention of future cases of
rubella and congenital rubella.
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